Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB
Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge represents Cinven in connection with the acquisition of Ongoing Warehouse

 Vinge has represented the international private equity firm Cinven in connection with its acquisition of Ongoing Warehouse.
May 06, 2026

Vinge advises Turbine Capital and Almi Invest GreenTech on an investment in Enairon

 Turbine Capital is leading a SEK 45 million investment round in the Swedish company Enairon, together with Almi Invest GreenTech, the European Innovation Council Fund, and existing investors. Enairon is a Swedish industrial company based in Halmstad, which develops a patented compressed air technology based on water and gravity, aimed at industrial companies globally where compressed air is a central part of production.
May 05, 2026

Vinge has represented Anaqua, a portfolio company of Nordic Capital, in connection with the acquisition of Patrix

 Vinge has represented Anaqua, Inc., a portfolio company of Nordic Capital, in connection with the acquisition of Patrix Aktiebolag, provider of IP management software and services. The acquisition is a strategic addition to Anaqua's platform, further expanding its European presence.
April 30, 2026